


BOMED²¹ South American Workshop

29-30 May 2017 | Rio de Janeiro

“Round table discussion: Toward a strategic science agenda for human-specific brain research and infrastructures”

Human-specific technologies & infrastructures

- If Brazilian funding bodies were to develop a 5-year strategic science agenda for human-specific health research, what are some key—
 - Investment priorities in enabling technologies (iPSC, organoids, organs-on-a-chip, etc.)?
 - Infrastructure needs (e.g., bioinformatics, HTS platforms, etc.)?
 - Needs for coordination among federal, state, other funders?
 - Opportunities for transnational collaboration (e.g., Brazil-Argentina, -EU, -USA)?
 - Legal, regulatory or other barriers to be overcome?
 - Incentives to prioritize non-animal approaches (e.g., _% more funding)?
 - Other considerations?



B₂OMED²¹ South American Workshop

29-30 May 2017 | Rio de Janeiro

“Round table discussion: Toward a strategic science agenda for human-specific brain research and infrastructures”

Adverse Outcome Pathway (AOP) development program

- How fully have the pathophysiological pathways/networks at the root of human brain disorders been elucidated?
- Could an AOP/systems biology framework be valuable in progressing research model and therapeutic product development in this area?
 - If so, what level of priority should be assigned to research of this nature?
- What would incentivize health scientists to contribute their knowledge of human disease pathophysiology to further populate open-access OECD AOP knowledge bases, e.g., funding, having an AOP wiki entry regarded as a peer reviewed publication, etc.?

B_{OX}MED²¹ South American Workshop

29-30 May 2017 | Rio de Janeiro

“Round table discussion: Toward a strategic science agenda for human-specific brain research and infrastructures”

Overarching questions

- In light of emerging technologies and conceptual thinking, should there be an overarching strategic review of human brain (or wider health) research and funding frameworks in order to incorporate the new approaches most effectively?
- Are there specific animal models that experts feel should no longer be used or funded (e.g., learned helplessness)?
- What are the main limitations of available human-specific technologies, and how can these be overcome?